Quest Diagnostics (DGX) agreed to acquire select assets of Fresenius Medical Care's (FMS) Spectra Laboratories unit, which provides renal-specific laboratory testing services in the US, the companies said Monday.
Under a separate deal, Quest will provide laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers that Fresenius and its wholly owned and joint-venture partners operate in the US, according to a joint statement.
Financial terms weren't disclosed.
The acquisition is expected to close in H2, while the transition of services is anticipated to be completed by early 2026, the companies added.
Shares of Quest were up more than 4% and Fresenius was 0.7% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。